Quick Dispatch:
Your glp 1 neuroendocrine tumor GLP1 and cancer: friend or foe? in: Endocrine-Related Cancer Volume 19 Issue 5 (2012) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp 1 neuroendocrine tumor GLP1 and cancer: friend or foe? in: Endocrine-Related Cancer Volume 19 Issue 5 (2012) ships.
Need Help?
Questions about glp 1 neuroendocrine tumor GLP1 and cancer: friend or foe? in: Endocrine-Related Cancer Volume 19 Issue 5 (2012), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp 1 neuroendocrine tumor GLP1 and cancer: friend or foe? in: Endocrine-Related Cancer Volume 19 Issue 5 (2012) in your area.
Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study
20.02
Oncology Reports
28.07
In a patient with a diagnosed neuroendocrine tumor and type 2 diabetes, is it safe to use glucagon‑like peptide‑1 (GLP‑1) receptor agonists such as exenatide (Byetta), liraglutide (Victoza), dulaglutide (Trulicity) or semaglutide (
28.64
750 Expression of GLP-1 Receptor in Well-Differentiated Neuroendocrine Tumors of Various Organ Sites: A Single-Institution Study
26.63
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
24.84
Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies in: Endocrine Oncology Volume 5 Issue 1 (2025)
28.92
The effect of glucagon-like peptide-1 receptor agonists on
25.13
